摘要
Aim:Our study aimed to explore the prognostic predictive potential of a novel RNA-based signature called ImmuneScore in advanced non-squamous NSCLC patients receiving combined immune checkpoint inhibitor(ICI)treatment and chemotherapy.Methods:RNA-sequencing data of 113 patients screened out from ORIENT-11 trial were retrospectively analyzed.ImmuneScore was calculated by the ESTIMATE algorithm.The association of ImmuneScore with early tumor progression,progression-free survival(PFS),and overall survival(OS)was analyzed using chi-square test,Cox regression test,and log-rank test.Receiver operating characteristic(ROC)curves were generated,with higher values of area under the ROC curves(AUCs)indicating better prediction ability.Results:ImmuneScore was negatively correlated with early tumor progression rate(4.3%vs.18.6%,P=0.013)while positively correlated with PFS(HR=0.29,95%CI:0.16-0.53,P<0.001)and OS(HR=0.32,95%CI:0.18-0.58,P<0.001),demonstrating higher AUCs than that of Programmed death-ligand 1(PD-L1)tumor proportion score(TPS)(early tumor progression:0.64 vs.0.68;PFS:0.67 vs.0.58;OS:0.73 vs.0.63).Nomograms integrating ImmuneScore and other significant variables(age and T-stage for PFS,gender and T-stage for OS)yielded good performance in PFS and OS prediction.Conclusion:ImmuneScore serves as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with ICI therapy.Higher ImmuneScore indicates lower early tumor progression rate,longer PFS,and longer OS.
基金
supported by the Medical Science and Technology Research Fund of Guangdong Province(Grant No.C2018062).
